Aimmune Therapeutics (AIMT) Stock Price Down 6.2%
Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) fell 6.2% during mid-day trading on Tuesday . The stock traded as low as $22.23 and last traded at $22.39. 895,172 shares changed hands during mid-day trading, an increase of 38% from the average session volume of 648,302 shares. The stock had previously closed at $23.86.
Several research firms have issued reports on AIMT. BidaskClub lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Cantor Fitzgerald initiated coverage on shares of Aimmune Therapeutics in a research report on Sunday. They issued a “buy” rating and a $64.00 price target on the stock. Credit Suisse Group set a $40.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Monday, November 19th. Roth Capital set a $80.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Monday, November 19th. Finally, Wedbush set a $80.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Monday, November 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $51.70.
The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -8.58 and a beta of -0.13.
In other news, insider Jayson Donald Alexander Dallas purchased 3,650 shares of the business’s stock in a transaction that occurred on Monday, November 19th. The stock was purchased at an average cost of $27.56 per share, with a total value of $100,594.00. Following the acquisition, the insider now directly owns 63,600 shares of the company’s stock, valued at approximately $1,752,816. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 14.70% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Tiverton Asset Management LLC bought a new position in shares of Aimmune Therapeutics in the second quarter worth about $145,000. Ardsley Advisory Partners bought a new position in shares of Aimmune Therapeutics in the second quarter worth about $202,000. Atria Investments LLC bought a new position in shares of Aimmune Therapeutics in the third quarter worth about $213,000. Xact Kapitalforvaltning AB bought a new position in shares of Aimmune Therapeutics in the third quarter worth about $221,000. Finally, Rehmann Capital Advisory Group raised its stake in shares of Aimmune Therapeutics by 2,242.4% in the third quarter. Rehmann Capital Advisory Group now owns 6,465 shares of the biotechnology company’s stock worth $237,000 after acquiring an additional 6,189 shares during the last quarter. 75.04% of the stock is owned by hedge funds and other institutional investors.
WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/aimmune-therapeutics-aimt-stock-price-down-6-2/2662485.html.
Aimmune Therapeutics Company Profile (NASDAQ:AIMT)
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Featured Story: What Are Treasury Bonds?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.